DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans
KE Ugen, SB Nyland, JD Boyer, C Vidal, L Lera… - Vaccine, 1998 - Elsevier
KE Ugen, SB Nyland, JD Boyer, C Vidal, L Lera, S Rasheid, M Chattergoon, ML Bagarazzi…
Vaccine, 1998•ElsevierHumoral and cellular immune responses have been produced by intramuscular vaccination
with DNA plasmids expressing HIV-1 genes, suggesting possible immunotherapeutic and
prophylactic value for these constructs. Vaccination with these constructs has decreased HIV-
1 viral load in HIV-1-infected chimpanzees. In addition, naive (ie non-HIV-1-infected)
chimpanzees were protected against a heterologous challenge with HIV-1. Ongoing phase I
clinical trials show that therapeutic vaccinations indeed boost anti-HIV-I immune responses …
with DNA plasmids expressing HIV-1 genes, suggesting possible immunotherapeutic and
prophylactic value for these constructs. Vaccination with these constructs has decreased HIV-
1 viral load in HIV-1-infected chimpanzees. In addition, naive (ie non-HIV-1-infected)
chimpanzees were protected against a heterologous challenge with HIV-1. Ongoing phase I
clinical trials show that therapeutic vaccinations indeed boost anti-HIV-I immune responses …
Humoral and cellular immune responses have been produced by intramuscular vaccination with DNA plasmids expressing HIV-1 genes, suggesting possible immunotherapeutic and prophylactic value for these constructs. Vaccination with these constructs has decreased HIV-1 viral load in HIV-1-infected chimpanzees. In addition, naive (i.e. non-HIV-1-infected) chimpanzees were protected against a heterologous challenge with HIV-1. Ongoing phase I clinical trials show that therapeutic vaccinations indeed boost anti-HIV-I immune responses in humans. A therapeutic phase I trial on humans with these constructs induced a good safety profile and also demonstrated an immunological potentiation. These findings indicate that further studies with these constructs in humans are warranted.
Elsevier